Navigation Links
Revised Medicaid policy could reduce unintended pregnancies, save millions in health costs

PITTSBURGH, Sept. 12, 2013 A revised Medicaid sterilization policy that removes logistical barriers, including a mandatory 30-day waiting period, could potentially honor women's reproductive decisions, reduce the number of unintended pregnancies and save $215 million in public health costs each year, according to researchers at the University of Pittsburgh School of Medicine. Their findings, published today in the journal Contraception, support growing evidence for the need to revisit a national policy that disproportionately affects low-income and minority women at high risk for unintended pregnancies.

Female sterilization, commonly called tubal ligation, is a permanent form of birth control performed as a surgical procedure to block a woman's fallopian tubes. According to the National Center for Health Statistics, it is the second-most commonly used contraceptive method in the United States. Each year, about 250,000 women request publicly funded sterilization through Medicaid, yet only 53 percent are able to have their sterilization requests fulfilled. Past research suggests that Medicaid regulations present significant obstacles because they mandate a 30-day waiting period between the time of written consent and the actual procedure and require that a physical copy of the form be present at the time of delivery for women undergoing post-partum sterilization.

"It's become evident that women who request federally funded sterilization are subject to a set of policy barriers that impede their reproductive autonomy," explained Sonya Borrero, M.D., M.S., assistant professor of medicine, Pitt School of Medicine, and lead author of the study. "The implementation of this policy during the 1970s was well-intentioned, erected in response to a history of coercive, non-consensual procedures mostly performed on low-income and minority women. However, there is now a body of evidence that indicates that the policy is not only incapable of serving its intended purpose, but also prevents the very same vulnerable population from obtaining a desired procedure, putting them at high risk for future unintended pregnancies."

To understand the cost savings that might result from a change in Medicaid sterilization policy, the researchers used existing data on the costs of Medicaid-funded sterilizations and Medicaid-covered births to construct a one-year cost effectiveness model from the health care payer's perspective. The model included all women who request Medicaid-funded post-partum sterilization and assumed that all pregnancies resulting after an unfulfilled sterilization request were unintended. The researchers then compared the costs of the existing policy to a hypothetically revised policy that removed logistical barriers.

They calculated that a revised Medicaid sterilization policy, including removal of the mandatory 30-day waiting period, would result in 29,000 fewer unintended pregnancies each year and thus lead to a cost savings of $215 million in taxpayer dollars.

The study suggested ways in which a modified policy could ensure patient comprehension, including improved readability of the consent form and decision-support tools to ensure that women are making fully informed decisions.

"Our study shows that existing federal policy should be modified to support both informed decision making and equitable access to a desired sterilization," advocated Dr. Borrero.


Contact: Andrea Stanford
University of Pittsburgh Schools of the Health Sciences

Related medicine news :

1. Standard & Poor’s Affirms Horizon Blue Cross Blue Shield of New Jersey’s Credit Rating of “A” - Affirmation Follows Review Under Revised Insurance Criteria
2. AAOS releases revised clinical practice guideline for osteoarthritis of the knee
3. Revised Sunscreen Labels Should Help Consumers Make Wiser Choices
4. Psychiatry Gets Revised Diagnostic Manual
5. Thyroid Treatment Guidelines for Pregnant Women Revised
6. Revised geographic adjustments could improve accuracy of Medicare payments, will not solve access, quality problems
7. Revised ARDS definition sets out levels of severity
8. Zane Benefits Publishes New Information on Health Insurance and Medicaid Eligibility
9. Medicaid pays for nearly half of all births in the United States
10. ATA Identifies States That Are Leading the Way in Telehealth Medicaid Coverage
11. Rural Medicaid Diabetes Program Judged "One of the Best Population Health Interventions Ever"
Post Your Comments:
(Date:10/13/2017)... WI (PRWEB) , ... October 13, 2017 , ... As ... in medicine known as “patient engagement.” The patient is doing more than filling out ... partners. , “There is an increasing emphasis in health care and research on ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: